More GAIN analysis

My guest post at Pharmalot is up on the GAIN Act. My bottom line:  the GAIN Act is not a balanced approach to reducing the burden of infectious disease.

Meanwhile, the most under-reported health story of the year continues, as PDUFA V emerged from the Conference Committee with the new “fast track” accelerated approval standards in place – essentially permitting more drugs to reach US patients with shorter and less complete clinical trials. This is a major change in the trade-off between safety, efficacy and market access, the biggest since the 1962 amendments.


Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on email

Hidden information below


* indicates required
Email Format